Respir Med Case Rep
The Hansoh deal fits with Mercks strategy in obesity, which according to CEO Robert Davis will center on small molecule oral drugs rather than injectable peptide treatments
Malfertheiner P, Megraud F, OMorain C, Gisbert JP, Kuipers EJ, Axon A, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar E, Agreus L, Andersen LP, Coelho L, Delchier JC, Di Mario F, Dinis-Ribeiro M, Fischbach W, Flahou B, Fock KM, Gasbarrini G, Gensini G, Goh KL, Herrero R, Kupcinskas L, Lanas A, Leja M, Machado JC, Mahachai V, Milosavljevic T, Niv Y, Ristimaki A, Tepes B, Vaira D, Vieth M, You W (2017) Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report
Head-to-Head Evidence (SURMOUNT-5) SURMOUNT-5 was the first large randomized clinical trial to compare tirzepatide and semaglutide directly at their respective maximum studied doses